In a large real-world PsA cohort, higher BMI reduced the odds of minimal disease activity, especially with TNF inhibitors other than infliximab.

In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.

Mease revisits the biggest PsA readouts from EULAR 2026: guselkumab, izokibep, GLP-1 combo therapy and more.

Baricitinib achieved glucocorticoid-free remission in 65% of patients with new-onset polymyalgia rheumatica at week 16, versus 17% with placebo.

Marta Mosca, MD, PhD, highlighted a 43.0% DORIS rate and a 74.1% LLDAS rate during the 12-month follow-up period with anifrolumab.

Jack Arnold and Rihards Buss preview 6 ACR 2026 abstracts spanning ICI arthritis, PsA proteomics, JAK inhibitor prescribing, and B-cell depletion.

The FDA approved tildrakizumab for adults with active psoriatic arthritis based on two phase 3 trials showing improved ACR20 response at week 24 vs placebo.

Buss and Arnolds discuss underscore persistent gaps between gout guideline recommendations and real-world practice.